nach oben

Acta Neuropathologica

Erschienen in:

01.09.2009 | Original Paper

Absence of α-synuclein pathology in postencephalitic parkinsonism

verfasst von: Kurt A. Jellinger

Erschienen in: Acta Neuropathologica | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Postencephalitic parkinsonism (PEP), a chronic complication of encephalitis lethargica, is a tauopathy characterized by multisystem neuronal loss and gliosis with widespread neurofibrillary lesions composed of both 3- and 4-repeat (3R and 4R) tau isoforms. Previous immunohistochemical studies in a small number of PEP cases demonstrated absence of Lewy bodies as well as the lack of other α-synuclein pathology, classifying PEP as a “pure” tauopathy. Neuropathologic examination of 10 brains with clinico-pathologically verified PEP confirmed widespread neurodegeneration in subcortical and brainstem areas associated with multifocal neurofibrillary pathology comprising both 3R and 4R tau. Very rare β-amyloid deposits were observed in two elderly patients, while Lewy bodies and neurites or any other α-synuclein deposits were completely absent. The causes and molecular background of total absence of α-synuclein pathology in PEP, in contrast to most other tauopathies, remain as unknown as the pathogenesis of PEP.

Arai T, Ikeda K, Akiyama H, Nonaka T, Hasegawa M, Ishiguro K, Iritani S, Tsuchiya K, Iseki E, Yagishita S, Oda T, Mochizuki A (2004) Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 55:72–79PubMedCrossRef

Buee-Scherrer V, Buee L, Leveugle B, Perl DP, Vermersch P, Hof PR, Delacourte A (1997) Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer’s disease and other neurodegenerative disorders. Ann Neurol 42:356–359PubMedCrossRef

Calne DB, Stern GM, Laurence DR, Sharkey J, Armitage P (1969) l-dopa in postencephalitic parkinsonism. Lancet 1:744–746PubMedCrossRef

Caparros-Lefebvre D, Cabaret M, Godefroy O, Steinling M, Remy P, Samson Y, Petit H (1998) PET study and neuropsychological assessment of a long-lasting post-encephalitic parkinsonism. J Neural Transm 105:489–495PubMedCrossRef

Delacourte A, Buee L (2000) Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol 13:371–376PubMedCrossRef

Delacourte A (2005) Alzheimer’s disease: a true tauopathy fueled by amyloid precursor protein dysfunction. In: Fisher A (ed) Progress in Alzheimer’s and Parkinson’s. Taylor & Francis, London, pp 301–307

DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW (2008) Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 65:1074–1080PubMedCrossRef

Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I (2002) Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935–946PubMed

Dickson DW, Fujishiro H, Delledonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115:437–444PubMedCrossRef

10.

Duvoisin RC, Lobo-Antunes J, Yahr MD (1972) Response of patients with postencephalitic Parkinsonism to levodopa. J Neurol Neurosurg Psychiatry 35:487–495PubMedCrossRef

11.

Espinoza M, de Silva R, Dickson DW, Davies P (2008) Differential incorporation of tau isoforms in Alzheimer’s disease. J Alzheimers Dis 14:1–16PubMed

12.

Feany MB, Mattiace LA, Dickson DW (1996) Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration. J Neuropathol Exp Neurol 55:53–67PubMedCrossRef

13.

Fenelon G, Goetz CG, Karenberg A (2006) Hallucinations in Parkinson disease in the prelevodopa era. Neurology 66:93–98PubMedCrossRef

14.

Foley PB (2009) Encephalitis lethargica and influenza. I. The role of the influenza virus in the influenza pandemic of 1918/1919. J Neural Transm 116:143–150PubMedCrossRef

15.

Forman MS, Schmidt ML, Kasturi S, Perl DP, Lee VM, Trojanowski JQ (2002) Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am J Pathol 160:1725–1731PubMed

16.

Geddes JF, Hughes AJ, Lees AJ, Daniel SE (1993) Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. Brain 116(Pt 1):281–302PubMedCrossRef

17.

Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM, Garruto RM, Perl DP, Galasko D, Lee VM, Trojanowski JQ (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115:133–145PubMedCrossRef

18.

Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636–640PubMedCrossRef

19.

Hallervorden J (1935) Anatomische Untersuchungen zur Pathogenese des postencephalitischen Parkinsonismus. Dtsch Z Nervenheilk 136:68–77CrossRef

20.

Haraguchi T, Ishizu H, Terada S, Takehisa Y, Tanabe Y, Nishinaka T, Kawai K, Kuroda S, Komoto Y, Namba M (2000) An autopsy case of postencephalitic parkinsonism of von Economo type: some new observations concerning neurofibrillary tangles and astrocytic tangles. Neuropathology 20:143–148PubMedCrossRef

21.

Henry JM, Jellinger KA (2003) Postencephalitic parkinsonism. In: Dickson DW (ed) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, pp 143–149

22.

Hernandez F, Avila J (2007) Tauopathies. Cell Mol Life Sci 64:2219–2233PubMedCrossRef

23.

Hof PR, Charpiot A, Delacourte A, Buee L, Purohit D, Perl DP, Bouras C (1992) Distribution of neurofibrillary tangles and senile plaques in the cerebral cortex in postencephalitic parkinsonism. Neurosci Lett 139:10–14PubMedCrossRef

24.

Hunter KR, Stern GM, Sharkey J (1970) Levodopa in postencephalitic parkinsonism. Lancet 2:1366–1367PubMedCrossRef

25.

Jellinger KA (1999) Movement disorders with tau protein cytoskeletal pathology. Adv Neurol 80:303–311PubMed

26.

Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:1219–1235PubMedCrossRef

27.

Jellinger KA (2005) The pathology of Parkinson’s disease—recent advances. In: Gálvez-Jiménez N (ed) Scientific basis for the treatment of Parkinson’s disease, 2nd edn. Taylor & Francis, London, pp 53–85

28.

Jellinger KA (2007) More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol 114:299–303PubMedCrossRef

29.

Jellinger KA (2007) Lewy body disorders. In: Youdim MBH, Riederer P, Mandel SA, Battistin L, Lajtha A (eds) Degenerative diseases of the nervous system. Springer Science, New York, pp 267–343

30.

Jellinger KA, Attems J (2007) Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol 113:107–117PubMedCrossRef

31.

Jellinger KA (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1–16PubMedCrossRef

32.

Jellinger KA (2009) Lewy body/alpha-synucleinopathy in schizophrenia and depression: a preliminary neuropathological study. Acta Neuropathol 117:423–427PubMedCrossRef

33.

Josephs KA, Parisi JE, Dickson DW (2002) Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. Neurology 59:645–646PubMed

34.

Katsuse O, Iseki E, Arai T, Akiyama H, Togo T, Uchikado H, Kato M, de Silva R, Lees A, Kosaka K (2003) 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 106:251–260PubMedCrossRef

35.

Keith-Rokosh J, Ang LC (2008) Progressive supranuclear palsy: a review of co-existing neurodegeneration. Can J Neurol Sci 35:602–608PubMed

36.

Lee VM, Giasson BI, Trojanowski JQ (2004) More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 27:129–134PubMedCrossRef

37.

Lees AJ (2003) Parkinson’s syndrome associated with neurofibrillary degeneration and tau pathologic findings. Mov Disord 18(Suppl 6):S28–S33PubMedCrossRef

38.

Litvan II, Jankovic J, Goetz CG, Wenning GK, Sastry N, Jellinger K, McKee A, Lai EC, Brandel JP, Verny M, Ray-Chaudhuri K, Pearce RK, Bartko JJ, Agid Y (1998) Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. Eur J Neurol 5:451–457PubMedCrossRef

39.

Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res 31:1153–1162PubMedCrossRef

40.

McCall S, Vilensky JA, Gilman S, Taubenberger JK (2008) The relationship between encephalitis lethargica and influenza: a critical analysis. J Neurovirol 14:177–185PubMedCrossRef

41.

Miklossy J, Steele JC, Yu S, McCall S, Sandberg G, McGeer EG, McGeer PL (2008) Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol 116:625–637PubMedCrossRef

42.

Mori H, Nishimura M, Namba Y, Oda M (1994) Corticobasal degeneration: a disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy. Acta Neuropathol 88:113–121PubMedCrossRef

43.

Mortimer PP (2009) Was encephalitis lethargica a post-influenzal or some other phenomenon? Time to re-examine the problem. Epidemiol Infect 137:449–455PubMedCrossRef

44.

Oyanagi K, Tsuchiya K, Yamazaki M, Ikeda K (2001) Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features. J Neuropathol Exp Neurol 60:393–402PubMed

45.

Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407PubMedCrossRef

46.

Picard F, Hirsch E, Salmon E, Marescaux C, Collard M (1996) Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to l-dopa. Rev Neurol (Paris) 152:267–271

47.

Ravenholt RT, Foege WH (1982) 1918 influenza, encephalitis lethargica, parkinsonism. Lancet 2:860–864PubMedCrossRef

48.

Shao CY, Crary JF, Rao C, Sacktor TC, Mirra SS (2006) Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies. J Neuropathol Exp Neurol 65:327–335PubMedCrossRef

49.

Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65:184–189PubMedCrossRef

50.

Tabaton M, Perry G, Autilio-Gambetti L, Manetto V, Gambetti P (1988) Influence of neuronal location on antigenic properties of neurofibrillary tangles. Ann Neurol 23:604–610PubMedCrossRef

51.

Togo T, Dickson DW (2002) Ballooned neurons in progressive supranuclear palsy are usually due to concurrent argyrophilic grain disease. Acta Neuropathol (Berl) 104:53–56CrossRef

52.

Tolnay M, Probst A (1999) REVIEW: tau protein pathology in Alzheimer’s disease and related disorders. Neuropathol Appl Neurobiol 25:171–187PubMedCrossRef

53.

Torvik A, Meen D (1966) Distribution of the brain stem lesions in postencephalitic Parkinsonism. Acta Neurol Scand 42:415–425PubMedCrossRef

54.

Tsuboi Y, Ahlskog JE, Apaydin H, Parisi JE, Dickson DW (2001) Lewy bodies are not increased in progressive supranuclear palsy compared with normal controls. Neurology 57:1675–1678PubMed

55.

Uchikado H, DelleDonne A, Uitti R, Dickson DW (2006) Coexistence of PSP and MSA: a case report and review of the literature. Acta Neuropathol 111:186–192PubMedCrossRef

56.

Uchikado H, Lin WL, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65:685–697PubMedCrossRef

57.

Ward CD (2003) Neuropsychiatric interpretations of postencephalitic movement disorders. Mov Disord 18:623–630PubMedCrossRef

58.

Wenning GK, Jellinger K, Litvan I (1997) Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. J Neural Transm 104:845–865PubMedCrossRef

59.

Yamazaki M, Hasegawa M, Mori O, Murayama S, Tsuchiya K, Ikeda K, Chen KM, Katayama Y, Oyanagi K (2005) Tau-positive fine granules in the cerebral white matter: a novel finding among the tauopathies exclusive to parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 64:839–846PubMedCrossRef

60.

Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG (2008) Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70:1042–1048PubMedCrossRef

61.

Zhukareva V, Shah K, Uryu K, Braak H, Del Tredici K, Sundarraj S, Clark C, Trojanowski JQ, Lee VM (2002) Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer’s disease, and Pick’s disease: a comparative study. Am J Pathol 161:1135–1141PubMed

Titel: Absence of α-synuclein pathology in postencephalitic parkinsonism
verfasst von: Kurt A. Jellinger
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: Acta Neuropathologica / Ausgabe 3/2009
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-009-0537-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Absence of α-synuclein pathology in postencephalitic parkinsonism

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer’s disease

Nitrosative stress and inducible nitric oxide synthase expression in periventricular leukomalacia

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma

Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes

p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis

Wolfram syndrome: a clinicopathologic correlation

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie